SCHEMBL2380381

SCHEMBL2380381

O=C1NCC=C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6636855 0.74
SCHEMBL1427438 0.67
SCHEMBL10315584 0.65
SCHEMBL6779911 0.65
SCHEMBL1926088 0.62
SCHEMBL7903760 0.62 ALDH1A1 (0.39)
SCHEMBL14467763 0.55
SCHEMBL1035336 0.54
SCHEMBL872865 0.54
SCHEMBL586833 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874596-A Synthetic method of alpha, beta-unsaturated gamma-lactam 华南理工大学 2025-04-25 CN disclosed
WO-2023196678-A2 4-PHENYL-2-PYRROLIDINONES AND METHODS OF USING THEREOF NORTH CAROLINA STATE UNIVERSITY (US) 2023-10-12 WO disclosed
WO-2023146844-A1 NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS UNIVERSITY OF HOUSTON SYSTEM (US) 2023-08-03 WO disclosed
US-20230234931-A1 NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS UNIVERSITY OF HOUSTON SYSTEM 2023-07-27 US disclosed
EP-3004110-B1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-07-26 EP disclosed
EP-3004110-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2016-04-13 EP disclosed
US-20160095843-A1 PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2016-04-07 US disclosed
EP-2686313-B1 BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-02-03 EP disclosed
CN-102791704-B The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5) PROBIODRUG AG (DE) 2015-11-25 CN disclosed
EP-2545047-B9 HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) PROBIODRUG AG (DE) 2015-06-10 EP disclosed
US-20120283259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2012-11-08 US disclosed
US-8269019-B2 Inhibitors PROBIODRUG AG (DE) 2012-09-18 US disclosed
WO-2011110613-A1 HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) PROBIODRUG AG (DE) 2011-09-15 WO disclosed
US-20110224254-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-6936633-B2 Pyrrolidinone derivatives UCB S.A. (BE) 2005-08-30 US disclosed
US-20050004180-A1 Pyrrolidinone derivatives USB S.A. (BE) 2005-01-06 US disclosed
US-6727275-B2 ANTIINFLAMMATORY, ANTIALLERGEN, AND ANTIASTHMATIC AGENTS UCB, S.A./N.V. (BE) 2004-04-27 US disclosed
US-4231933-A Novel 3-hydroxy-pyrrolin-2-one derivatives WARNER-LAMBERT COMPANY (US) 1980-11-04 US disclosed
US-4231933-A Novel 3-hydroxy-pyrrolin-2-one derivatives WARNER-LAMBERT COMPANY (US) 1980-11-04 US disclosed
US-4231933-A Novel 3-hydroxy-pyrrolin-2-one derivatives WARNER-LAMBERT COMPANY (US) 1980-11-04 US disclosed